Adult Acute Myeloid Leukemia With T(8;21)(q22;q22) Completed Phase 2 Trials for Tacrolimus (DB00864)

Also known as: Adult Acute Myeloid Leukemia With t(8;21)(q22;q22)

IndicationStatusPhase
DBCOND0036073 (Adult Acute Myeloid Leukemia With T(8;21)(q22;q22))Completed2
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT01707004Decitabine and Total-Body Irradiation Followed By Donor Bone Marrow Transplant and Cyclophosphamide in Treating Patients With Relapsed or Refractory Acute Myeloid LeukemiaTreatment
NCT01529827Fludarabine Phosphate, Melphalan, and Low-Dose Total-Body Irradiation Followed by Donor Peripheral Blood Stem Cell Transplant in Treating Patients With Hematologic MalignanciesTreatment
NCT01789255Vorinostat, Tacrolimus, and Methotrexate in Preventing GVHD After Stem Cell Transplant in Patients With Hematological MalignanciesSupportive Care
NCT00860574Treosulfan, Fludarabine Phosphate, and Total-Body Irradiation Before Donor Stem Cell Transplant in Treating Patients With High-Risk Acute Myeloid Leukemia, Myelodysplastic Syndrome, Acute Lymphoblastic LeukemiaTreatment
NCT00049504Fludarabine Phosphate, Cyclophosphamide, Tacrolimus, Mycophenolate Mofetil, Total-Body Irradiation, and Donor Bone Marrow Transplant in Treating Patients With High-Risk Hematologic CancerTreatment
NCT00489203Beclomethasone Dipropionate in Preventing Acute Graft-Versus-Host Disease in Patients Undergoing a Donor Stem Cell Transplant for Hematologic CancerSupportive Care
NCT01056614Fludarabine Phosphate, Busulfan, and Anti-Thymocyte Globulin Followed By Donor Peripheral Blood Stem Cell Transplant, Tacrolimus, and Methotrexate in Treating Patients With Myeloid MalignanciesTreatment